Superworth

Seaport Therapeutics EPS SPTX

Diluted earnings per share by quarter and over the last twelve months, from 2025.

Last 12 months, to Sep 30, 2026
n/m
a quarter missing
Latest quarter, Q3 FY26
−$0.49

Seaport Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY26, it was −$0.49.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Quarter by quarter

QuarterEndedEPSOn a year earlier
Q3 FY26−$0.49n/a
Q2 FY26−$1.78n/a
Q1 FY26−$10.34n/a
Q3 FY25−$9.43n/a
Q2 FY25−$6.40n/a
Q1 FY25−$5.65n/a

Against its peers

Companies in Drug Manufacturers - General nearest Seaport Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
SPTXSeaport Therapeuticsn/m
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
ANABAnaptysbio$4.57
ABUSArbutus Biopharma$0.78
PCRXPacira BioSciences$0.35
COLLCollegium Pharmaceutical$1.24+19% a year
PAHCPhibro Animal Health$2.44+107% a year
ANIPANI Pharmaceuticals$4.70
ZVRAZevra Therapeutics$0.93
IRWDIronwood Pharmaceuticals$0.77
Peer median$1.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Seaport Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.